Krishnan Viswanadhan

Krishnan Viswanadhan

Adjunct Professor

School of Pharmacy and Health Sciences



  • Clinical Trial Design and Regulatory Requirements
  • U.S. Regulatory New Drug Application and Submission
  • Dossier Preparation Regulatory Strategy


  • BS, Rutgers University
  • PharmD, Ernest Mario School of Pharmacy
  • MBA, Cornell University


  • Regulatory Science
  • Drug Development
  • Cell Therapies
  • Biotechnology and entrepreneurship

Academic Profile

Dr. Viswanadhan joined the School of Pharmacy and Health Sciences in 2016 as Adjunct Professor.  Dr. Viswanadhan is a registered Pharmacist and received his Bachelor of Science and Doctor of Pharmacy degrees from the Ernest Mario School of Pharmacy.  Following graduation, Dr. Viswanadhan completed an industrial post-doctoral fellowship at Rutgers University and Roche Pharmaceuticals in Regulatory Science and was an Adjunct faculty member at Ernest Mario School of Pharmacy.   Dr. Viswanadhan also received his Master’s in Business Administration degree from Cornell University in 2010.

Dr. Viswanadhan has held multiple roles in the pharmaceutical industry with over 20 years of broad cross-functional experiences in various roles in regulatory strategy, clinical development,  business development, program/project leadership with a focus on advancing new medicines for patients with serious and life-threatening diseases.

Dr. Viswanadhan is currently President and Chief Operating Officer at Be Biopharma, a leader in engineered B cells as a new category of medicines for patients with serious diseases. Prior to Be Biopharma, Krishnan was Senior Vice President, Global Cell Therapy Franchise Lead at Bristol Myers Squibb where he was responsible for overseeing the integrated cell therapy franchise strategy across the enterprise including building core capabilities and key investments to support long-term growth. He oversaw the teams responsible for the development, FDA approval, and life cycle management of Breyanzi, a CD19 CAR T, and Abecma, the first BCMA CAR T therapy. He has been involved in the regulatory strategy and development of multiple novel therapies including small molecules, biologics, and cell-based therapies.

Dr. Viswanadhan currently serves on the board of directors of JW Therapeutics and Cargo Therapeutics.

Important Note: Faculty profiles may include links to one or more non-FDU websites, including websites self-maintained by faculty to provide additional information about their publications, scholarly pursuits, and other information of interest. If you click on these links, you will be leaving the FDU-maintained website and will be directed to a site that is not under the control of FDU. FDU is not responsible for the content or accessibility of linked non-FDU websites. If, however, you experience a problem with the content or accessibility of a linked website, please contact us using the information on our Accessibility page.